Versartis, Inc. (NASDAQ:VSAR) is scheduled to be releasing its earnings data after the market closes on Wednesday, July 26th. Analysts expect Versartis to post earnings of ($0.84) per share for the quarter.

Versartis (NASDAQ:VSAR) last posted its earnings results on Thursday, April 27th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.14. On average, analysts expect Versartis to post $-2.94 EPS for the current fiscal year and $-2.91 EPS for the next fiscal year.

Shares of Versartis, Inc. (NASDAQ VSAR) opened at 17.50 on Wednesday. The firm’s 50 day moving average price is $16.93 and its 200 day moving average price is $17.70. The stock’s market cap is $616.14 million. Versartis, Inc. has a 52-week low of $9.05 and a 52-week high of $24.00.

Several research analysts have recently weighed in on the stock. BidaskClub cut shares of Versartis from a “buy” rating to a “hold” rating in a research note on Sunday. Canaccord Genuity set a $28.00 price target on shares of Versartis and gave the stock a “buy” rating in a research note on Sunday, May 28th. Zacks Investment Research upgraded shares of Versartis from a “sell” rating to a “hold” rating in a research note on Thursday, June 29th. Piper Jaffray Companies set a $26.00 price target on shares of Versartis and gave the stock a “buy” rating in a research note on Tuesday, June 27th. Finally, ValuEngine upgraded shares of Versartis from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $25.13.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/07/19/versartis-inc-vsar-to-release-quarterly-earnings-on-wednesday.html.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Earnings History for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.